KRAS Mutations and Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases

被引：11
作者：
Velho, Sergia [1 ]
Oliveira, Carla [1 ,2 ]
Seruca, Raquel [1 ,2 ]
机构：
[1] Univ Porto, Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal
[2] Univ Porto, Fac Med, P-4100 Oporto, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 01期
关键词：
CETUXIMAB; PANITUMUMAB; BRAF;
D O I：
10.1200/JCO.2008.20.1525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 159
页数：3
相关论文
共 14 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer [J].
Artale, Salvatore ;
Sartore-Bianchi, Andrea ;
Veronese, Silvio Marco ;
Gambi, Valentina ;
Sarnataro, Carolina Silvia ;
Gambacorta, Marcello ;
Lauricella, Calogero ;
Siena, Salvatore .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4217-4219
[3]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[4]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[5]   KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature [J].
de Reynies, Aurelien ;
Biol, Valerie ;
Milano, Gerard ;
Faivre, Jean ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :228-2230
[6]   KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].
De Roock, W. ;
Piessevaux, H. ;
De Schutter, J. ;
Janssens, M. ;
De Hertogh, G. ;
Personeni, N. ;
Biesmans, B. ;
Van Laethem, J. -L. ;
Peeters, M. ;
Humblet, Y. ;
Van Cutsem, E. ;
Tejpar, S. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515
[7]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[8]   Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone [J].
Freeman, Daniel J. ;
Juan, Todd ;
Reiner, Maureen ;
Hecht, J. Randolph ;
Meropol, Neal J. ;
Berlin, Jordan ;
Mitchell, Edith ;
Sarosi, Ildiko ;
Radinsky, Robert ;
Amado, Rafael G. .
CLINICAL COLORECTAL CANCER, 2008, 7 (03) :184-190
[9]   Cetuximab for the treatment of colorectal cancer [J].
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Karapetis, Christos S. ;
Zalcberg, John R. ;
Tu, Dongsheng ;
Au, Heather-Jane ;
Berry, Scott R. ;
Krahn, Marianne ;
Price, Timothy ;
Simes, R. John ;
Tebbutt, Niall C. ;
van Hazel, Guy ;
Wierzbicki, Rafal ;
Langer, Christiane ;
Moore, Malcolm J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048
[10]   KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].
Lièvre, A ;
Bachet, JB ;
Le Corre, D ;
Boige, V ;
Landi, B ;
Emile, JF ;
Côté, JF ;
Tomasic, G ;
Penna, C ;
Ducreux, M ;
Rougier, P ;
Penault-Llorca, F ;
Laurent-Puig, P .
CANCER RESEARCH, 2006, 66 (08) :3992-3995
12